RxDoctor Payments Data

Noel Sanchez, MD

Colon & Rectal Surgery · Wichita, KSNPI 1861437386

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (52.8%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 87.7% of it on its own, with 12 other manufacturers making up the rest.

$14,207in general payments, 2019–2025

Across 79 payments — averaging $179.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$12K
  • Medtronic$441
  • Axonics, Inc.$435
  • Davol Inc.$369
  • AbbVie$178
  • Conmed Corporation$128
  • plus $201 from 7 others
$951,465in research payments, 2019–2025

Across 110 payments — averaging $8649.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$944K
  • Davol Inc.$7K

What the payments were for

  • Speaking & faculty fees$1501%
  • Travel & lodging$3,28323%
  • Food & beverage$3,25823%
  • Education$7,50053%
  • Gifts$160%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few colon & rectal surgery providers in Kansasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$177,885
Medicare patients
371
Services billed
1,558

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GattexTeduglutide12$571,817
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates178$12,347
LoperamideLoperamide Hcl12$523
Neomycin Sulfate57$266
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen24$221
Metronidazole60$120
Pantoprazole Sodium33$107

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gattex$19$571,81712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few colon & rectal surgery providers in Kansason file to place this against a meaningful peer group, so we don't.

Other colon & rectal surgery in Wichita

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →